CA2238263A1 - Pulverisateur d'hydrocortisone pour administration topique - Google Patents

Pulverisateur d'hydrocortisone pour administration topique Download PDF

Info

Publication number
CA2238263A1
CA2238263A1 CA002238263A CA2238263A CA2238263A1 CA 2238263 A1 CA2238263 A1 CA 2238263A1 CA 002238263 A CA002238263 A CA 002238263A CA 2238263 A CA2238263 A CA 2238263A CA 2238263 A1 CA2238263 A1 CA 2238263A1
Authority
CA
Canada
Prior art keywords
dermal
appropriate
pharmaceutical composition
component
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002238263A
Other languages
English (en)
Inventor
Hans Georg Weder
Marc Antoine Weder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vesifact AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2238263A1 publication Critical patent/CA2238263A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une préparation pharmaceutique d'application dermique d'hydrocortisone. Ce principe actif est dispersé par adjonction d'un ester d'acide gras partiel de sorbitanne de polyéthylène et d'autres auxiliaires tels que la lécithine et l'huile neutre. Ce système permet d'obtenir une suspension de particules de l'ordre du nanomètre du principe actif hydrocortisone liphophile.
CA002238263A 1995-12-12 1996-12-09 Pulverisateur d'hydrocortisone pour administration topique Abandoned CA2238263A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH3499/95 1995-12-12
CH349995 1995-12-12

Publications (1)

Publication Number Publication Date
CA2238263A1 true CA2238263A1 (fr) 1997-06-19

Family

ID=4257316

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002238263A Abandoned CA2238263A1 (fr) 1995-12-12 1996-12-09 Pulverisateur d'hydrocortisone pour administration topique

Country Status (4)

Country Link
EP (1) EP0866689A1 (fr)
AU (1) AU7689996A (fr)
CA (1) CA2238263A1 (fr)
WO (1) WO1997021428A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008638B2 (en) 1998-05-11 2006-03-07 Ciba Specialty Chemicals Corporation Use of nanodispersions in cosmetic end formulations
US7381423B2 (en) 1998-05-11 2008-06-03 Ciba Specialty Chemicals Corp. Use of nanodispersions in cosmetic end formulations

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59710082D1 (de) * 1996-12-13 2003-06-18 Vesifact Ag Baar Kosmetische Präparate in Form einer Nanodispersion
TWI241915B (en) * 1998-05-11 2005-10-21 Ciba Sc Holding Ag A method of preparing a pharmaceutical end formulation using a nanodispersion
AU5405399A (en) * 1998-09-14 2000-04-03 Vesifact Ag Utilization of nanocells in final culture medium products
JP2002533379A (ja) 1998-12-23 2002-10-08 イデア アクチェンゲゼルシャフト 生体内における局所的に非侵襲性である用途のための改善された製剤
FR2820320B1 (fr) * 2001-02-02 2003-04-04 Oreal Suspension de nanospheres de principe actif lipophile stabilisee par des polymeres hydrodispersibles
EP1256337A1 (fr) * 2001-05-08 2002-11-13 Vesifact Ag Méthode et compositions pour appliquer un agent sur un substrat
KR100772327B1 (ko) 2004-04-22 2007-10-31 주식회사유한양행 하이드로코티손 또는 그 염을 함유하는 나노에멀젼 조성물
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
CL2008000037A1 (es) * 2007-01-16 2008-10-10 Bayer Consumer Care Ag Solucion coloidal que comprende al menos un ingrediente activo, al menos una molecula formadora de membrana y al menos un componente espumante; procedimiento para fabricar la solucion coloidal; y su uso para tratar trastornos dermatologicos.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2648462B1 (fr) * 1989-06-15 1994-01-28 Oreal Procede pour ameliorer l'efficacite therapeutique de corticosteroides liposolubles et composition pour la mise en oeuvre de ce procede
US5260065A (en) * 1991-09-17 1993-11-09 Micro Vesicular Systems, Inc. Blended lipid vesicles
IL101387A (en) * 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
EP0711556A1 (fr) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Solutions intraveineuses contenant des dérivés de staurosporine
WO1996037192A1 (fr) * 1995-05-26 1996-11-28 Vesifact Ag Compositions pharmaceutiques et cosmetiques contenant des sphingolipides et des glycolipides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008638B2 (en) 1998-05-11 2006-03-07 Ciba Specialty Chemicals Corporation Use of nanodispersions in cosmetic end formulations
US7381423B2 (en) 1998-05-11 2008-06-03 Ciba Specialty Chemicals Corp. Use of nanodispersions in cosmetic end formulations

Also Published As

Publication number Publication date
AU7689996A (en) 1997-07-03
WO1997021428A1 (fr) 1997-06-19
EP0866689A1 (fr) 1998-09-30

Similar Documents

Publication Publication Date Title
US5152923A (en) Process for the production of a nanoemulsion of oil particles in an aqueous phase
US6245349B1 (en) Drug delivery compositions suitable for intravenous injection
EP0852941B1 (fr) Composiotn cosmétique sous forme d'une nanodispersion
EP0315079A1 (fr) Supports de médicaments
EP2405896B1 (fr) Glycérosomes et leur utilisation dans des préparations pharmaceutiques et cosmétiques pour application topique
EP0733358A2 (fr) Nanosuspensions pour application intraveineuse
IL129921A (en) Topical and transdermal delivery compositions utilizing submicron oil droplets and these compositions comprising an active ingredient
JPH0549334B2 (fr)
EP0211258A2 (fr) Micro-émulsions
CA2162342A1 (fr) Solutions intraveineuses pour un derive de la staurosporine
EP1013268A1 (fr) Compositions contenant des liposomes et/ou des emulsions et leur procede de preparation
EP2515865B1 (fr) Composition cutanée comprenant un analogue de la vitamine d et un mélange de solvant et de tensioactifs
CA2238263A1 (fr) Pulverisateur d'hydrocortisone pour administration topique
JPH05186333A (ja) 眼用組成物
CN111867562A (zh) 不溶性药物的水性制剂
CH684308A5 (de) Liposomen enthaltend ein Allylamin.
CA2495913A1 (fr) Formulations lipidiques cationiques non vesiculaires
EP3381517B1 (fr) Agrégats vesiculaires tridimensionels de phospholipides, diffusés dans des mileux alcooliques avec pas d'eau ou un contenu d'eau très bas, leur préparation et leur usage dans des formulations pour usage topique.
WO1992003123A1 (fr) Formulations alternatives de liposomes a double couche
JPH035426A (ja) 安定な電解質含有レシチン分散液
WO1991016039A1 (fr) Procede pour la fabrication de suspensions aqueuses de liposomes contenant des matieres actives
WO2021046374A2 (fr) Systèmes d'administration de microémulsion pour espèces solubles dans l'alcool, notamment des hormones non dérivatisées
US20230114405A1 (en) Microemulsion Delivery Systems for A Female Hormone Blend with Alcohol-Soluble Species Including Nonderivatized Hormones
WO2023076042A1 (fr) Systèmes d'administration transdermique de microémulsion pour des espèces solubles dans l'alcool comprenant des hormones non dérivées
EP0467838A2 (fr) Procédé de préparation d'une dispersion des liposomes injectable

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20001211